Katsuto Takenaka

Title: Katsuto Takenaka: Innovator in Hematological Research

Introduction

Katsuto Takenaka is an inventor based in Fukuoka, Japan. He is known for his contributions to the field of hematological research. Although he currently holds no granted patents, his work focuses on enhancing hematopoietic stem cell engraftment and improving prognostic methods for patients with hematological cancers.

Latest Patent Applications

Katsuto Takenaka has filed several notable patent applications. One of his latest applications is titled "MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR." This invention relates to modulating the SIRPα-CD47 interaction to increase hematopoietic stem cell engraftment. It includes isolated SIRPα and CD47 polypeptides, fragments, and fusion proteins aimed at enhancing this engraftment. Additionally, methods for increasing hematopoietic stem cell engraftment through the administration of these polypeptides are provided.

Another significant application is "LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER." This method involves determining prognosis in subjects with hematological cancer by measuring gene expression levels of a set of genes from a leukemic stem cell (LSC) or hematopoietic stem cell (HSC) gene signature marker set. The results classify subjects as having either a good or poor prognosis based on their expression profile.

Conclusion

Katsuto Takenaka is making strides in the field of hematological research through his innovative patent applications. His work has the potential to significantly impact the treatment and prognosis of patients with hematological cancers.